Review

. 2017 Nov;18(11):e653-e706.

doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31.

Future cancer research priorities in the USA: a Lancet Oncology Commission

Elizabeth M Jaffee¹, Chi Van Dang², David B Agus³, Brian M Alexander⁴, Kenneth C Anderson⁴, Alan Ashworth⁵, Anna D Barker⁶, Roshan Bastani⁷, Sangeeta Bhatia⁸, Jeffrey A Bluestone⁹, Otis Brawley¹⁰, Atul J Butte⁵, Daniel G Coit¹¹, Nancy E Davidson¹², Mark Davis¹³, Ronald A DePinho¹⁴, Robert B Diasio¹⁵, Giulio Draetta¹⁴, A Lindsay Frazier⁴, Andrew Futreal¹⁴, Sam S Gambhir¹⁶, Patricia A Ganz⁷, Levi Garraway¹⁷, Stanton Gerson¹⁸, Sumit Gupta¹⁹, James Heath¹³, Ruth I Hoffman²⁰, Cliff Hudis²¹, Chanita Hughes-Halbert²², Ramy Ibrahim²³, Hossein Jadvar²⁴, Brian Kavanagh²⁵, Rick Kittles²⁶, Quynh-Thu Le¹⁶, Scott M Lippman²⁷, David Mankoff²⁸, Elaine R Mardis²⁹, Deborah K Mayer³⁰, Kelly McMasters³¹, Neal J Meropol³², Beverly Mitchell¹⁶, Peter Naredi³³, Dean Ornish⁵, Timothy M Pawlik³⁴, Jeffrey Peppercorn³⁵, Martin G Pomper³⁶, Derek Raghavan³⁷, Christine Ritchie⁵, Sally W Schwarz³⁸, Richard Sullivan³⁹, Richard Wahl³⁸, Jedd D Wolchok⁴⁰, Sandra L Wong⁴¹, Alfred Yung¹⁴

Affiliations

¹ The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ejaffee@jhmi.edu.
² Ludwig Institute for Cancer Research New York, NY; Wistar Institute, Philadelphia, PA, USA. Electronic address: cdang@licr.org.
³ University of Southern California, Beverly Hills, CA, USA.
⁴ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁵ University of California San Francisco, San Francisco, CA, USA.
⁶ Arizona State University, Tempe, AZ, USA.
⁷ Fielding School of Public Health and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
⁸ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁹ University of California San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
¹⁰ American Cancer Society, Atlanta, GA, USA.
¹¹ Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
¹² Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
¹³ California Institute for Technology, Pasadena, CA, USA.
¹⁴ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁵ Mayo Clinic Cancer Center, Rochester, MN, USA.
¹⁶ Stanford University, Stanford, CA, USA.
¹⁷ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA; Eli Lilly and Company, Boston, MA, USA.
¹⁸ Case Comprehensive Cancer Center, Cleveland, OH, USA.
¹⁹ Division of Haematology/Oncology, Hospital for Sick Children, Faculty of Medicine and IHPME, University of Toronto, Toronto, Canada.
²⁰ American Childhood Cancer Organization, Beltsville, MD, USA.
²¹ Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
²² Medical University of South Carolina and the Hollings Cancer Center, Charleston, SC, USA.
²³ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
²⁴ Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
²⁵ Department of Radiation Oncology, University of Colorado, Denver, CO, USA.
²⁶ College of Medicine, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
²⁷ University of California San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
²⁸ Department of Radiology and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
²⁹ The Institute for Genomic Medicine at Nationwide Children's Hospital Columbus, OH, USA; College of Medicine, Ohio State University, Columbus, OH, USA.
³⁰ University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.
³¹ The Hiram C Polk Jr MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.
³² Flatiron Health, New York, NY, USA.
³³ Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
³⁴ Department of Surgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
³⁵ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³⁶ The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³⁷ Levine Cancer Institute, Carolinas HealthCare, Charlotte, NC, USA.
³⁸ Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.
³⁹ King's College London, London, UK.
⁴⁰ Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁴¹ Department of Surgery, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

PMID: 29208398
PMCID: PMC6178838
DOI: 10.1016/S1470-2045(17)30698-8

Review

Future cancer research priorities in the USA: a Lancet Oncology Commission

Elizabeth M Jaffee et al. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):e653-e706.

doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31.

Authors

Affiliations

¹ The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ejaffee@jhmi.edu.
² Ludwig Institute for Cancer Research New York, NY; Wistar Institute, Philadelphia, PA, USA. Electronic address: cdang@licr.org.
³ University of Southern California, Beverly Hills, CA, USA.
⁴ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁵ University of California San Francisco, San Francisco, CA, USA.
⁶ Arizona State University, Tempe, AZ, USA.
⁷ Fielding School of Public Health and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
⁸ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁹ University of California San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
¹⁰ American Cancer Society, Atlanta, GA, USA.
¹¹ Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
¹² Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
¹³ California Institute for Technology, Pasadena, CA, USA.
¹⁴ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁵ Mayo Clinic Cancer Center, Rochester, MN, USA.
¹⁶ Stanford University, Stanford, CA, USA.
¹⁷ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA; Eli Lilly and Company, Boston, MA, USA.
¹⁸ Case Comprehensive Cancer Center, Cleveland, OH, USA.
¹⁹ Division of Haematology/Oncology, Hospital for Sick Children, Faculty of Medicine and IHPME, University of Toronto, Toronto, Canada.
²⁰ American Childhood Cancer Organization, Beltsville, MD, USA.
²¹ Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
²² Medical University of South Carolina and the Hollings Cancer Center, Charleston, SC, USA.
²³ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
²⁴ Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
²⁵ Department of Radiation Oncology, University of Colorado, Denver, CO, USA.
²⁶ College of Medicine, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
²⁷ University of California San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
²⁸ Department of Radiology and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
²⁹ The Institute for Genomic Medicine at Nationwide Children's Hospital Columbus, OH, USA; College of Medicine, Ohio State University, Columbus, OH, USA.
³⁰ University of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.
³¹ The Hiram C Polk Jr MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.
³² Flatiron Health, New York, NY, USA.
³³ Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
³⁴ Department of Surgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
³⁵ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³⁶ The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³⁷ Levine Cancer Institute, Carolinas HealthCare, Charlotte, NC, USA.
³⁸ Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.
³⁹ King's College London, London, UK.
⁴⁰ Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁴¹ Department of Surgery, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

PMID: 29208398
PMCID: PMC6178838
DOI: 10.1016/S1470-2045(17)30698-8

Abstract

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

PubMed Disclaimer

Conflict of interest statement

Declarations of interests

DBA serves on the Board of Directors for Tempus, Applied Proteomics, and the Biden Foundation Cancer Initiative. BMA reports personal fees from Bristol-Myers Squibb, Abbvie, Schlesinger Health Associates, and Precision Health Economics. KCA reports personal fees from Millennium Takeda, Bristol-Myers Squibb, and Gilead. JAB reports personal fees from Arcus and FlxBio, and grants and personal fees from Juno and Pfizer. AJB reports personal fees from NuMedii, Personalis, Roche, Genentech, and Pfizer. DM reports personal fees from G ealthcare and Blue Earth Diagnostics, and grants from Siemens Heathcare. ALF reports consulting and stock from Decibel Therapeutics. JH is the Founder and Director of PACT Therapeutics and of Isoplexis, and has equity in Isoplexis. EMJ reports grants and personal fees from Aduro Biotech and grants from Bristol-Myers Squibb. DKM reports stock in Carevive. KMcM is on the Board of Directors for Provectus Biopharmaceuticals, on the Scientific Advisory Board for Elucida Oncology, and holds a patent on characterising melanoma using RNA, miRNA, and polypeptides. NJM is a full-time employee of Flatiron Health, and has a patent pending for systems and methods for matching patients with clinical trials. DO reports personal fees from Sharecare for consultancy. MGP has patents pending for various theranostic imaging agents. Q-TL reports grants from Varian Medical Systems and Redhill Biopharma, and travel assistance from Bristol-Myers Squibb. RW is a consultant for Nihon MediPhysics. JDW reports grants from Bristol-Myers Squibb, Merck, MedImmune, Genentech, and Immunocore and is a consultant for Bristol-Myers Squibb, Merck, MedImmune, and Genentech. AA is a consultant for Genentech, AtlasMDX, Third Rock Ventures, Pfizer, Sun Pharma, and Bluestar, receives research support from Sun Pharma, is a co-founder of Tango Therapeutics, and holds patents on the use of PARP inhibitors jointly with AstraZeneca. All other authors declare no competing interests. LG’s contributions to this report is solely related to his research at the Massachusetts Institute of Technology.

Figures

**Figure 1:. A selection of leading US cancer research institutes along with publication output, total citations, and field-weighted citation impact (FWCI), 2011–15**
World average for FWCI 1.00. Adapted with permission from the Elsevier Cancer Research Report.

**Figure 2:. Field-weighted citation impact in cancer research, medicine, and all disciplines for selected countries in 2014**
Source: Scopus. Adapted with permission from the Elsevier Cancer Research Report.

See this image and copyright information in PMC

Comment in

An action plan for cancer control in the USA.
Collingridge D, Coburn C. Collingridge D, et al. Lancet Oncol. 2017 Nov;18(11):e619. doi: 10.1016/S1470-2045(17)30789-1. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208376 No abstract available.
Priorities for cancer research in the USA.
Simon GC. Simon GC. Lancet Oncol. 2017 Nov;18(11):e620-e621. doi: 10.1016/S1470-2045(17)30786-6. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208377 No abstract available.
Implementing the Cancer Moonshot and beyond.
Lowy DR, Singer DS. Lowy DR, et al. Lancet Oncol. 2017 Nov;18(11):e622-e623. doi: 10.1016/S1470-2045(17)30797-0. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208378 Free PMC article. No abstract available.
Patients, data, and progress in cancer care.
Chrischilles EA, Friedman S, Ritzwoller DP, Selby JV. Chrischilles EA, et al. Lancet Oncol. 2017 Nov;18(11):e624-e625. doi: 10.1016/S1470-2045(17)30796-9. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208379 No abstract available.
The Cancer Moonshot from a European perspective.
Ciardiello F, Tabernero J. Ciardiello F, et al. Lancet Oncol. 2017 Nov;18(11):e626. doi: 10.1016/S1470-2045(17)30798-2. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208380 No abstract available.
Groundshot: a pan-European, patient-centred, and data-driven approach to tackling cancer.
Costa M, Collingridge D. Costa M, et al. Lancet Oncol. 2023 Jan;24(1):5-6. doi: 10.1016/S1470-2045(22)00651-9. Epub 2022 Nov 16. Lancet Oncol. 2023. PMID: 36400099 No abstract available.

References

1. National Cancer Institute. Cancer Moonshot. Blue Ribbon Panel Report 2016. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiati... (accessed Sept 30, 2017).
1. Lowy DR, Collins FS. Aiming high—changing the trajectory for cancer. N Engl J Med 2016; 374: 1901–04. - PMC - PubMed
1. Elsevier. Cancer research Current trends & future directions. Amsterdam: Elsevier, 2016.
1. Emmons KM, Colditz GA. Realizing the potential of cancer prevention—the role of implementation science. N Engl J Med 2017; 376: 986–90. - PMC - PubMed
1. Kerr J, Anderson CA, Lippman SM. Physical activity, sedentary behavior, diet, and cancer: an update and emerging new evidence. Lancet Oncol 2017; 18: e457–71. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Future cancer research priorities in the USA: a Lancet Oncology Commission

Affiliations

Future cancer research priorities in the USA: a Lancet Oncology Commission

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials